INSMED INC
StreetZero Signal 68
About INSMED INC
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is a first-in-disease treatment, with additional pipeline focus including ARIKAYCE for nontuberculous mycobacteria lung disease. The company is publicly traded on NASDAQ under ticker INSM and maintains headquarters in Bridgewater Township, New Jersey.
LATEST FUNDINGRule 144
$14.7M
Announced 2026-11-19
TOTAL RAISED$4.57B
IN THE NEWS
- ๐ Insmed Incorporated
- ๐ Insmed Announces Proposed $500 Million Public Offering of Common Stock
- ๐ Insmed Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
- ๐ Insmed - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- ๐ INSMED INCORPORATED
EMPLOYEESโ
FOUNDEDโ
HQBridgewater Township, New Jersey, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyPublic CompanyRare DiseasesBiopharmaceutical
Investors
Key highlights
- Publicly traded on NASDAQ: INSM with focus on serious and rare diseases.
- Completed $14.7M Rule 144 placement with undisclosed investors.
- Total funding of $4.57B across 17 rounds including multiple post-IPO equity raises.
- First commercial product targets unmet needs in nontuberculous mycobacteria lung disease.
Ask StreetZero about INSMED INC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account